MapLight Raises $296.5mln, Funds Through 2027, Trials Expected in H2 2026-27

• MapLight Therapeutics reports Q3 2025 results and financials. • Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in H2 2026. • Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in H2 2027. • Raised $296.5 million in gross proceeds from IPO and private placement in October 2025. • Cash, cash equivalents and short-term investments sufficient to fund operations through 2027.